Resection as first-line therapy for large hepatic sclerosing hemangioma: a case report

Abstract: Hepatic sclerosing hemangioma is a rare benign disease that occurs in association with hepatic cavernous hemangioma degeneration and sclerosis. Recent studies have shown that radiofrequency (RF) ablation is an alternative treatment for hepatic cavernous hemangiomas, even for large hemangiomas (≥10 cm). However, RF ablation might not be suitable to treat large sclerosing hemangiomas. We herein report the successful surgical removal of a large hepatic sclerosing hemangioma after RF ablation treatment failure in a 65-year-old man. In conclusion, we suggest that resection should be chosen as a first-line therapy for the disease.

Keywords: resection, radiofrequency ablation, hepatic cavernous hemangiomas, hepatic sclerosing hemangioma

Introduction

Hepatic cavernous hemangioma is one of the most frequently encountered benign hepatic neoplasms, but hepatic sclerosed hemangioma is very rare.1-8 Hemangioma degeneration can occur through an increase in the degree of fibrosis and thrombosis of its vascular channels, a condition that is known as sclerosing and/or hyalinizing hemangioma. This can then lead to the end stage, known as the involution stage, in which the hemangioma becomes completely sclerosed and/or hyalinized.1-3 The frequency of cavernous hemangioma acquiring sclerosis does not seem to be high, and lesion formation requires many years.4

Most accidentally identified and asymptomatic hepatic hemangiomas do not require medical intervention. When hemangiomas are larger than 5.0 cm and cause abdominal symptoms, or increase in size during follow-up, radical interventions need to be considered.9-15 Traditionally, surgery is the most commonly used treatment of choice, including hemangioma enucleation, lobectomy (segmentectomy) or partial hepatectomy, and tumor suture or ligation. However, surgery is rather invasive and is associated with relatively high risks of perioperative morbidity (27%) and mortality (3%), and also with long hospitalization.9,10 In recent years, radiofrequency (RF) ablation has been increasingly used to treat hepatic cavernous hemangiomas because of its unique advantages, such as minimal invasiveness, efficacy, high safety, fast recovery, and wide applicability.9,11-15 Recent studies have shown that RF ablation is an alternative treatment for hepatic cavernous hemangiomas, even large hemangiomas (≥10 cm).13-15 However, it might not be suitable for the treatment of large sclerosing hemangiomas.

We herein report the case of a patient with successful surgical removal of large hepatic sclerosing hemangioma after RF ablation treatment failure. We also discuss the best therapy course for the disease.
A 65-year-old Chinese man was admitted to our hospital with an enlarging hepatic hemangioma following regular follow-up imaging over 16 years and complaints of intermittent abdominal pain for 2 years. Sixteen years ago, a tumor measuring 4.5 cm was accidentally identified in the right lobe of liver. A fine-needle biopsy was performed, and hepatic cavernous hemangioma was confirmed by histology. The tumor mass was found to be increasing in size upon regular imaging follow-up and it was not palpable by physical examination.

Contrast-enhanced MRI showed a large hepatic cavernous hemangioma in the right lobe (16.7×15.9 cm) (Figure 1A–C). Laboratory examinations including routine blood tests, biochemistry tests for liver, renal and coagulation function, and tumor markers did not show any abnormalities. Based on our accumulated experience of treating large hepatic cavernous hemangiomas with RF ablation [9], we treated the patient with RF ablation via a laparoscopic approach as the first-line treatment. We used a Cool-tip ACTC2025 electrode (an internally cooled cluster electrode) and an RF generator (Covidien).

Figure 1 Contrast-enhanced MRI showing a 16.7-cm hepatic hemangioma in the right lobe (A–C). Two months after laparoscopic RF ablation, contrast-enhanced-CT revealed that only one-third of the tumor was ablated (red arrow), and the ablated tumor had not shrunk (D–F). Tumor resection was performed by intratumoral coagulation using RF ablation (G). The large hemangioma was removed, and the left lobe of liver was left. The white arrow indicates the inferior vena cava (H). Macroscopic appearance of the tumor. The tumor was composed of solid grey-white masses indicating sclerosing hemangiomas and dark red sponge-like masses indicating cavernous hemangiomas (I and J). The tumor mainly comprised hyalinized tissue and collagen fibers (left) with thin-walled and variably cavernous vascular channels lined by endothelial cells (right) on sections (hematoxylin and eosin staining, H&E, ×40) (K). A higher magnification of the hepatic sclerosing hemangioma showed abundant hyalinized tissue and collagen fibers with sporadic vascular spaces (H&E, ×100) (L). Postoperative contrast-enhanced CT follow-up confirmed that the hemangioma was completely dissected without any residual tissue one month after the surgery (M–O).
Hepatic sclerosing hemangiomas are caused by degenerative changes such as recent hemorrhages, hemosiderin deposits, thrombus formation, necrosis, and scar formation in hepatic cavernous hemangiomas. This can then lead to the end stage, in which the hemangioma becomes completely sclerosed and/or hyalinized. Sclerosing hemangioma accompanies cavernous hemangioma or preexisting cavernous hemangioma changes to sclerosed hemangioma over a period of many years. Characteristically, in the present case, both sclerosing hemangioma and cavernous hemangiomas were synchronously found inside the tumor, which was valuable in providing insight into the development process from cavernous hemangioma to sclerosing hemangioma.

Hepatic sclerosing hemangiomas are caused by degenerative changes such as thrombus formation, necrosis, and scar formation within liver cavernous hemangioma, and such variations in the pathological characteristics make precise radiological diagnosis very difficult. Sclerosing hemangioma is frequently misdiagnosed as an intrahepatic malignancy or metastatic lesions, for which a hepatectomy is performed. In the present case, the preoperative contrast MRI captured a large hepatic cavernous hemangioma and the sclerosing hemangioma could not be detected, because most of the tumor was composed of cavernous hemangiomas. Additionally, based on our accumulated experience of treating large hepatic cavernous hemangiomas with RF ablation, we selected RF ablation as a first-line strategy to manage the tumor.

RF ablation for hepatic cavernous hemangiomas is performed using RF-induced thermal energy to damage the endothelial cell-lined vascular structures resulting from thrombosis promotion, to induce necrotic coagulation, and to destroy erythrocytes and cause vascular smooth muscle cell disappearance and fibrosis in the ablated zone. One well-performed ablation session for a hepatic cavernous hemangioma can lead to a clear collapse of the tumor tissue around the ablation zone, making RF ablation for hepatic cavernous hemangiomas more efficient and easier to perform compared with malignant hepatic lesions. Meanwhile, the collapse of the tumor is also the basis for the relief of abdominal symptoms after ablation treatment. However, sclerosing hemangiomas are characterized by extensive fibrosis with subsequent hyalinization and marked narrowing or obliteration of the vascular spaces, which makes the texture of the tumor very tough, just like intrahepatic malignancies or metastatic lesions. Thus, only one-third of the tumor was ablated in the present case, and the ablated tumor did not shrink even after prolonged ablation. Therefore, when the texture of hepatic cavernous hemangiomas is found to be tough during surgery, accompanied...
sclerosing hemangioma should be considered, and hepatic resection should be the first-line therapy.

In conclusion, hepatic sclerosing hemangioma is a rare benign disease, and occurs in association with the degeneration and sclerosis of cavernous hemangiomas of the liver. We suggest that resection should be an option for first-line therapy of the disease.

Ethics approval
We confirm that written informed consent was provided by the patient to have their case details and any accompanying images published. Institutional approval was not required to publish the case details.

Acknowledgment
We thank H. Nikki March, PhD and Jodi Smith, PhD, from Liwen Bianji, Edanz Editing China, for editing a draft of this manuscript. This study was supported by the Program for High-level Technical Talents in the Beijing Health System (2015-03-025).

Disclosure
The authors report no conflicts of interest in this work.

References